Stock Analysis, Dividends, Split History

QHC / Quorum Health Corporation financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)142.13
Enterprise Value ($M)1,351.70
Book Value ($M)-23.31
Book Value / Share-0.75
Price / Book-6.10
NCAV ($M)-1,153.80
NCAV / Share-37.34
Price / NCAV-0.12
Share Statistics
Common Shares Outstanding 30,201,415
Common Stock Shares Outstanding 30,294,895
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.09
Return on Assets (ROA)-0.06
Return on Equity (ROE)-0.56
Balance Sheet (mrq) ($M)
Quick Ratio1.40
Current Ratio1.54
Income Statement (mra) ($M)
Health Care Organization Revenue Net Of Patient Service Revenue Provisions2,072,170,000.00
Contractual Allowances Included In Health Care Organization Patient Service Revenue9,173,711,000.00
Health Care Organization Revenue2,327,655,000.00
Health Care Organization Patient Service Revenue11,930,145,000.00
Health Care Organization Patient Service Revenue Provisionfor Bad Debts255,485,000.00
Discounts Included In Health Care Organization Patient Service Revenue428,779,000.00
Operating Income-12.14
Net Income-112.36
Earnings Per Share Basic And Diluted-4.06
Cash Flow Statement (mra) ($M)
Cash From Operations66.97
Cash from Investing-38.27
Cash from Financing-38.27
Identifiers and Descriptors
Central Index Key (CIK)1650445
Related CUSIPS

Split History

Stock splits are used by Quorum Health Corporation to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Quorum Health Corporation (QHC) CEO Bob Fish on Q2 2018 Results - Earnings Call Transcript

2018-08-10 seekingalpha
Quorum Health Corporation (NYSE:QHC) Q2 2018 Results Earnings Conference Call August 9, 2018 11:00 AM ET (1-0)

3 Ideas For August 2018: P/E Vs. EV/EBITDA

2018-08-01 seekingalpha
People who use EBITDA are either trying to con you or they're conning themselves." - Warren Buffett (30-2)

What Falling Estimates & Price Mean for Quorum Health (QHC)

2018-06-04 zacks
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio. One such stock that you may want to consider dropping is Quorum Health Corporation (QHC - Free Report) , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. (8-0)

Quorum Health Corporation 2018 Q1 - Results - Earnings Call Slides

2018-05-10 seekingalpha
The following slide deck was published by Quorum Health Corporation in conjunction with their 2018 Q1 earnings call. (4-1)

CUSIP: 74909E106